Vertex reports interim data from Phase II ZENITH study
The data showed that viral loads were below the lower limit of quantification for 80% (37/46) of patients with genotype 1 hepatitis C at week two and 83%
Evogene and ELEO have entered a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the Proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway for hyperlipidemia and cardiovascular diseases.
Northera has received orphan drug designation from the FDA to treat rare diseases/disorders. Neurogenic OH is a chronic neurogenic disorder resulting from deficient release of norepinephrine, the neurotransmitter